Roland W. Herzog - Publications

University of Florida, Gainesville, Gainesville, FL, United States 
Immunology, Molecular Biology, Microbiology Biology, Virology Biology

143 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Bertolini TB, Biswas M, Terhorst C, Daniell H, Herzog RW, Piñeros AR. Role of orally induced regulatory T cells in immunotherapy and tolerance. Cellular Immunology. 359: 104251. PMID 33248367 DOI: 10.1016/j.cellimm.2020.104251  1
2020 Biswas M, Marsic D, Li N, Zou C, Gonzalez-Aseguinolaza G, Zolotukhin I, Kumar SRP, Rana J, Butterfield JSS, Kondratov O, de Jong YP, Herzog RW, Zolotukhin S. Engineering and Selection of a Novel AAV3B Variant with High Hepatocyte Tropism and Reduced Seroreactivity. Molecular Therapy. Methods & Clinical Development. 19: 347-361. PMID 33145371 DOI: 10.1016/j.omtm.2020.09.019  1
2020 Herzog RW, Biswas M. Neutralizing the Neutralizers in AAV Gene Therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 32697940 DOI: 10.1016/j.ymthe.2020.07.015  1
2020 Brown HC, Doering CB, Herzog R, Ling C, Markusic DM, Spencer HT, Srivastava A, Srivastava A. Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B. Human Gene Therapy. PMID 32657150 DOI: 10.1089/hum.2020.099  1
2020 Zou C, Vercauteren KOA, Michailidis E, Kabbani M, Zoluthkin I, Quirk C, Chiriboga L, Yazicioglu M, Anguela XM, Meuleman P, High KA, Herzog RW, de Jong YP. Experimental Variables that Affect Human Hepatocyte AAV Transduction in Liver Chimeric Mice. Molecular Therapy. Methods & Clinical Development. 18: 189-198. PMID 32637450 DOI: 10.1016/j.omtm.2020.05.033  1
2020 Kumar SRP, Wang X, Avuthu N, Bertolini TB, Terhorst C, Guda C, Daniell H, Herzog RW. Role of Small Intestine and Gut Microbiome in Plant-Based Oral Tolerance for Hemophilia. Frontiers in Immunology. 11: 844. PMID 32508814 DOI: 10.3389/fimmu.2020.00844  1
2020 Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune Responses to Viral Gene Therapy Vectors. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 31968213 DOI: 10.1016/j.ymthe.2020.01.001  1
2020 Michailidis E, Vercauteren K, Mancio-Silva L, Andrus L, Jahan C, Ricardo-Lax I, Zou C, Kabbani M, Park P, Quirk C, Pyrgaki C, Razooky B, Verhoye L, Zoluthkin I, Lu WY, ... ... Herzog RW, et al. Expansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes. Proceedings of the National Academy of Sciences of the United States of America. PMID 31915293 DOI: 10.1073/pnas.1919035117  1
2019 Shirley JL, Keeler GD, Sherman A, Zolotukhin I, Markusic DM, Hoffman BE, Morel LM, Wallet MA, Terhorst C, Herzog RW. Type I IFN Sensing by cDCs and CD4 T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8 T Cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 31780366 DOI: 10.1016/j.ymthe.2019.11.011  1
2019 Yigit B, Wang N, Ten Hacken E, Chen SS, Bhan AK, Suarez Fueyo A, Katsuyama E, Tsokos GC, Chiorazzi N, Wu CJ, Burger J, Herzog RW, Engel P, Terhorst C. SLAMF6 as a regulator of exhausted CD8+ T cells in cancer. Cancer Immunology Research. PMID 31315913 DOI: 10.1158/2326-6066.CIR-18-0664  1
2019 Daniell H, Kulis M, Herzog RW. Plant cell-made protein antigens for induction of Oral tolerance. Biotechnology Advances. PMID 31251968 DOI: 10.1016/j.biotechadv.2019.06.012  1
2019 Butterfield JSS, Biswas M, Shirley JL, Kumar SRP, Sherman A, Terhorst C, Ling C, Herzog R. TLR9-activating CpG-B ODN but not TLR7 Agonists Trigger Antibody Formation to Factor IX in Muscle Gene Transfer. Human Gene Therapy Methods. PMID 31140323 DOI: 10.1089/hgtb.2019.013  1
2019 Wang N, Yigit B, van der Poel CE, Cuenca M, Carroll MC, Herzog RW, Engel P, Terhorst C. The Checkpoint Regulator SLAMF3 Preferentially Prevents Expansion of Auto-Reactive B Cells Generated by Graft-vs.-Host Disease. Frontiers in Immunology. 10: 831. PMID 31057553 DOI: 10.3389/fimmu.2019.00831  1
2019 Herzog RW, Kuteyeva V, Saboungi R, Terhorst C, Biswas M. Reprogrammed CD4 T Cells That Express FoxP3 Control Inhibitory Antibody Formation in Hemophilia A Mice. Frontiers in Immunology. 10: 274. PMID 30842776 DOI: 10.3389/fimmu.2019.00274  1
2019 Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of Current Technologies and Methods. Methods in Molecular Biology (Clifton, N.J.). 1950: 333-360. PMID 30783984 DOI: 10.1007/978-1-4939-9139-6_20  1
2018 Perrin GQ, Herzog RW, Markusic DM. Update on clinical gene therapy for hemophilia. Blood. PMID 30559260 DOI: 10.1182/blood-2018-07-820720  1
2018 Yigit B, Wang N, Herzog RW, Terhorst C. SLAMF6 in health and disease: Implications for therapeutic targeting. Clinical Immunology (Orlando, Fla.). PMID 30366106 DOI: 10.1016/j.clim.2018.10.013  1
2018 Sherman A, Biswas M, Herzog RW. Tolerance induction in hemophilia: innovation and accomplishments. Current Opinion in Hematology. PMID 29994897 DOI: 10.1097/MOH.0000000000000446  1
2018 Xiao W, Gao G, Ling C, Herzog RW, Xiao X, Samulski RJ. Impact of neutralizing antibodies against AAV is a key consideration in gene transfer to nonhuman primates. Nature Medicine. PMID 29867233 DOI: 10.1038/s41591-018-0062-2  1
2018 Biswas M, Kumar SRP, Terhorst C, Herzog RW. Gene Therapy With Regulatory T Cells: A Beneficial Alliance. Frontiers in Immunology. 9: 554. PMID 29616042 DOI: 10.3389/fimmu.2018.00554  1
2017 Sherman A, Biswas M, Herzog RW. Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A. Frontiers in Immunology. 8: 1604. PMID 29225598 DOI: 10.3389/fimmu.2017.01604  1
2017 Corti M, Liberati C, Smith BK, Lawson LA, Tuna IS, Conlon TJ, Erger KE, Islam S, Herzog R, Fuller DD, Collins S, Byrne BJ. Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in children affected by Pompe Disease. Human Gene Therapy. Clinical Development. PMID 29160099 DOI: 10.1089/humc.2017.146  0.44
2017 Kwon KC, Sherman A, Chang WJ, Kamesh A, Biswas M, Herzog RW, Daniell H. Expression and assembly of largest foreign protein in chloroplasts: Oral delivery of human FVIII made in lettuce chloroplasts robustly suppresses inhibitor formation in hemophilia A mice. Plant Biotechnology Journal. PMID 29106782 DOI: 10.1111/pbi.12859  1
2017 Herzog RW, Cooper M, Perrin GQ, Biswas M, Martino AT, Morel L, Terhorst C, Hoffman BE. Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer. Cellular Immunology. PMID 28888664 DOI: 10.1016/j.cellimm.2017.07.012  1
2017 Palaschak B, Marsic D, Herzog RW, Zolotukhin S, Markusic DM. An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8(+) T Cells. Molecular Therapy. Methods & Clinical Development. 5: 142-152. PMID 28480313 DOI: 10.1016/j.omtm.2017.04.004  1
2017 Wang X, Herzog RW, Byrne BJ, Kumar SRP, Zhou Q, Buchholz CJ, Biswas M. Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells. Molecular Therapy. Methods & Clinical Development. 5: 76-82. PMID 28480307 DOI: 10.1016/j.omtm.2017.03.005  1
2017 Rogers GL, Shirley JL, Zolotukhin I, Kumar SRP, Sherman A, Perrin GQ, Hoffman BE, Srivastava A, Basner-Tschakarjan E, Wallet MA, Terhorst C, Biswas M, Herzog RW. Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8(+) T cells. Blood. 129: 3184-3195. PMID 28468798 DOI: 10.1182/blood-2016-11-751040  1
2017 Markusic DM, Nichols TC, Merricks EP, Palaschak B, Zolotukhin I, Marsic D, Zolotukhin S, Srivastava A, Herzog RW. Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models. Journal of Translational Medicine. 15: 94. PMID 28460646 DOI: 10.1186/s12967-017-1200-1  1
2017 Kumar SR, Hoffman BE, Terhorst C, de Jong YP, Herzog RW. The Balance between CD8(+) T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose. Molecular Therapy : the Journal of the American Society of Gene Therapy. 25: 880-891. PMID 28284982 DOI: 10.1016/j.ymthe.2017.02.014  1
2017 Herzog RW, Nichols TC, Su J, Zhang B, Sherman A, Merricks EP, Raymer R, Perrin GQ, Häger M, Wiinberg B, Daniell H. Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce. Molecular Therapy : the Journal of the American Society of Gene Therapy. 25: 512-522. PMID 28153098 DOI: 10.1016/j.ymthe.2016.11.009  1
2017 Biswas M, Rogers GL, Sherman A, Byrne BJ, Markusic DM, Jiang H, Herzog RW. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin. Thrombosis and Haemostasis. 117: 33-43. PMID 27683758 DOI: 10.1160/TH16-05-0404  1
2016 Perrin GQ, Zolotukhin I, Sherman A, Biswas M, de Jong YP, Terhorst C, Davidoff AM, Herzog RW. Dynamics of antigen presentation to transgene product-specific CD4(+) T cells and of Treg induction upon hepatic AAV gene transfer. Molecular Therapy. Methods & Clinical Development. 3: 16083. PMID 27933310 DOI: 10.1038/mtm.2016.83  1
2016 Zolotukhin I, Markusic DM, Palaschak B, Hoffman BE, Srikanthan MA, Herzog RW. Potential for cellular stress response to hepatic factor VIII expression from AAV vector. Molecular Therapy. Methods & Clinical Development. 3: 16063. PMID 27738644 DOI: 10.1038/mtm.2016.63  1
2016 Kumar SR, Markusic DM, Biswas M, High KA, Herzog RW. Clinical development of gene therapy: results and lessons from recent successes. Molecular Therapy. Methods & Clinical Development. 3: 16034. PMID 27257611 DOI: 10.1038/mtm.2016.34  1
2016 Vercauteren K, Hoffman BE, Zolotukhin I, Keeler GD, Xiao JW, Basner-Tschakarjan E, High KA, Ertl HC, Rice CM, Srivastava A, de Jong YP, Herzog RW. Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. Molecular Therapy : the Journal of the American Society of Gene Therapy. 24: 1042-1049. PMID 27019999 DOI: 10.1038/mt.2016.61  1
2016 Doerfler PA, Nayak S, Corti M, Morel L, Herzog RW, Byrne BJ. Targeted approaches to induce immune tolerance for Pompe disease therapy. Molecular Therapy. Methods & Clinical Development. 3: 15053. PMID 26858964 DOI: 10.1038/mtm.2015.53  1
2016 Xiao Y, Kwon KC, Hoffman BE, Kamesh A, Jones NT, Herzog RW, Daniell H. Low cost delivery of proteins bioencapsulated in plant cells to human non-immune or immune modulatory cells. Biomaterials. 80: 68-79. PMID 26706477 DOI: 10.1016/j.biomaterials.2015.11.051  1
2016 Doerfler PA, Todd AG, Clément N, Falk DJ, Nayak S, Herzog RW, Byrne BJ. Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease. Human Gene Therapy. 27: 43-59. PMID 26603344 DOI: 10.1089/hum.2015.103  1
2016 Wang X, Terhorst C, Herzog RW. In vivo induction of regulatory T cells for immune tolerance in hemophilia. Cellular Immunology. 301: 18-29. PMID 26454643 DOI: 10.1016/j.cellimm.2015.10.001  1
2015 Berns KI, Byrne BJ, Flotte TR, Gao G, Hauswirth WW, Herzog RW, Muzyczka N, VandenDriessche T, Xiao X, Zolotukhin S, Srivastava A. Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma? Human Gene Therapy. 26: 779-81. PMID 26690810 DOI: 10.1089/hum.2015.29014.kib  0.44
2015 Corti M, Cleaver B, Clément N, Conlon TJ, Faris KJ, Wang G, Benson J, Tarantal AF, Fuller D, Herzog RW, Byrne BJ. Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning. Human Gene Therapy. Clinical Development. 26: 185-93. PMID 26390092 DOI: 10.1089/humc.2015.068  0.44
2015 Su J, Zhu L, Sherman A, Wang X, Lin S, Kamesh A, Norikane JH, Streatfield SJ, Herzog RW, Daniell H. Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B. Biomaterials. 70: 84-93. PMID 26302233 DOI: 10.1016/j.biomaterials.2015.08.004  1
2015 Biswas M, Terhorst C, Herzog RW. Treg: tolerance vs immunity. Oncotarget. 6: 19956-7. PMID 26119156 DOI: 10.18632/oncotarget.4648  1
2015 Su J, Sherman A, Doerfler PA, Byrne BJ, Herzog RW, Daniell H. Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice. Plant Biotechnology Journal. 13: 1023-32. PMID 26053072 DOI: 10.1111/pbi.12413  1
2015 Doerfler PA, Nayak S, Herzog RW, Morel L, Byrne BJ. BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease. Clinical Immunology (Orlando, Fla.). 158: 140-7. PMID 25842186 DOI: 10.1016/j.clim.2015.03.022  1
2015 Biswas M, Sarkar D, Kumar SR, Nayak S, Rogers GL, Markusic DM, Liao G, Terhorst C, Herzog RW. Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg. Blood. 125: 2937-47. PMID 25833958 DOI: 10.1182/blood-2014-09-599266  1
2015 Wang X, Su J, Sherman A, Rogers GL, Liao G, Hoffman BE, Leong KW, Terhorst C, Daniell H, Herzog RW. Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells. Blood. 125: 2418-27. PMID 25700434 DOI: 10.1182/blood-2014-08-597070  1
2015 Rogers GL, Suzuki M, Zolotukhin I, Markusic DM, Morel LM, Lee B, Ertl HC, Herzog RW. Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer. Journal of Innate Immunity. 7: 302-14. PMID 25612611 DOI: 10.1159/000369273  1
2014 Sack BK, Herzog RW, Terhorst C, Markusic DM. Development of Gene Transfer for Induction of Antigen-specific Tolerance. Molecular Therapy. Methods & Clinical Development. 1: 14013. PMID 25558460 DOI: 10.1038/mtm.2014.13  1
2014 Corti M, Elder M, Falk D, Lawson L, Smith B, Nayak S, Conlon T, Clément N, Erger K, Lavassani E, Green M, Doerfler P, Herzog R, Byrne B. B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Molecular Therapy. Methods & Clinical Development. 1. PMID 25541616 DOI: 10.1038/mtm.2014.33  0.32
2014 Sarkar D, Biswas M, Liao G, Seay HR, Perrin GQ, Markusic DM, Hoffman BE, Brusko TM, Terhorst C, Herzog RW. Ex Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia. Molecular Therapy. Methods & Clinical Development. 1. PMID 25364772 DOI: 10.1038/mtm.2014.30  1
2014 Marsic D, Govindasamy L, Currlin S, Markusic DM, Tseng YS, Herzog RW, Agbandje-McKenna M, Zolotukhin S. Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1900-9. PMID 25048217 DOI: 10.1038/mt.2014.139  1
2014 Nayak S, Doerfler PA, Porvasnik SL, Cloutier DD, Khanna R, Valenzano KJ, Herzog RW, Byrne BJ. Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent. Plos One. 9: e98336. PMID 24897114 DOI: 10.1371/journal.pone.0098336  1
2014 Markusic DM, Herzog RW. A David promoter with Goliath strength. Blood. 123: 3068-9. PMID 24832942 DOI: 10.1182/blood-2014-04-565507  1
2014 Sherman A, Su J, Lin S, Wang X, Herzog RW, Daniell H. Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells. Blood. 124: 1659-68. PMID 24825864 DOI: 10.1182/blood-2013-10-528737  1
2014 Wang X, Moghimi B, Zolotukhin I, Morel LM, Cao O, Herzog RW. Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1139-1150. PMID 24609143 DOI: 10.1038/mt.2014.43  1
2014 Sherman A, Schlachterman A, Cooper M, Merricks EP, Raymer RA, Bellinger DA, Herzog RW, Nichols TC. Portal vein delivery of viral vectors for gene therapy for hemophilia. Methods in Molecular Biology (Clifton, N.J.). 1114: 413-26. PMID 24557919 DOI: 10.1007/978-1-62703-761-7_27  1
2014 Liao G, O'Keeffe MS, Wang G, van Driel B, de Waal Malefyt R, Reinecker HC, Herzog RW, Terhorst C. Glucocorticoid-Induced TNF Receptor Family-Related Protein Ligand is Requisite for Optimal Functioning of Regulatory CD4(+) T Cells. Frontiers in Immunology. 5: 35. PMID 24550919 DOI: 10.3389/fimmu.2014.00035  1
2014 Rogers GL, Martino AT, Zolotukhin I, Ertl HC, Herzog RW. Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. Journal of Translational Medicine. 12: 25. PMID 24460861 DOI: 10.1186/1479-5876-12-25  1
2014 Liao G, van Driel B, Magelky E, O'Keeffe MS, de Waal Malefyt R, Engel P, Herzog RW, Mizoguchi E, Bhan AK, Terhorst C. Glucocorticoid-induced TNF receptor family-related protein ligand regulates the migration of monocytes to the inflamed intestine. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 28: 474-84. PMID 24107315 DOI: 10.1096/fj.13-236505  1
2013 Markusic DM, Hoffman BE, Perrin GQ, Nayak S, Wang X, LoDuca PA, High KA, Herzog RW. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. Embo Molecular Medicine. 5: 1698-709. PMID 24106230 DOI: 10.1002/emmm.201302859  1
2013 Hoffman BE, Herzog RW. Covert warfare against the immune system: decoy capsids, stealth genomes, and suppressors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1648-50. PMID 24008618 DOI: 10.1038/mt.2013.176  1
2013 Elder ME, Nayak S, Collins SW, Lawson LA, Kelley JS, Herzog RW, Modica RF, Lew J, Lawrence RM, Byrne BJ. B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. The Journal of Pediatrics. 163: 847-54.e1. PMID 23601496 DOI: 10.1016/j.jpeds.2013.03.002  1
2013 Tremblay JP, Xiao X, Aartsma-Rus A, Barbas C, Blau HM, Bogdanove AJ, Boycott K, Braun S, Breakefield XO, Bueren JA, Buschmann M, Byrne BJ, Calos M, Cathomen T, Chamberlain J, ... ... Herzog RW, et al. Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 266-8. PMID 23369965 DOI: 10.1038/mt.2013.4  1
2013 Martino AT, Basner-Tschakarjan E, Markusic DM, Finn JD, Hinderer C, Zhou S, Ostrov DA, Srivastava A, Ertl HC, Terhorst C, High KA, Mingozzi F, Herzog RW. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood. 121: 2224-33. PMID 23325831 DOI: 10.1182/blood-2012-10-460733  1
2013 Suzuki M, Bertin TK, Rogers GL, Cela RG, Zolotukhin I, Palmer DJ, Ng P, Herzog RW, Lee B. Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 796-805. PMID 23319058 DOI: 10.1038/mt.2012.277  0.36
2013 Wang X, Sherman A, Liao G, Leong KW, Daniell H, Terhorst C, Herzog RW. Mechanism of oral tolerance induction to therapeutic proteins. Advanced Drug Delivery Reviews. 65: 759-73. PMID 23123293 DOI: 10.1016/j.addr.2012.10.013  1
2013 Kwon KC, Verma D, Singh ND, Herzog R, Daniell H. Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Advanced Drug Delivery Reviews. 65: 782-99. PMID 23099275 DOI: 10.1016/j.addr.2012.10.005  1
2012 Markusic DM, Herzog RW. Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia. Journal of Genetic Syndromes & Gene Therapy. 1: 1-9. PMID 23565343 DOI: 10.4172/2157-7412.S1-009  1
2012 Perrin GQ, Herzog RW. Making dendritic cells that turn immune responses off. Human Gene Therapy. 23: ix-xi. PMID 22822900 DOI: 10.1089/hum.2012.2514  1
2012 Hoffman BE, Ertl HC, Terhorst C, High KA, Herzog RW. Gene therapy research at the frontiers of viral immunology. Frontiers in Microbiology. 3: 182. PMID 22783235 DOI: 10.3389/fmicb.2012.00182  1
2012 Sack BK, Merchant S, Markusic DM, Nathwani AC, Davidoff AM, Byrne BJ, Herzog RW. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy. Plos One. 7: e37671. PMID 22655063 DOI: 10.1371/journal.pone.0037671  1
2012 Nayak S, Sivakumar R, Cao O, Daniell H, Byrne BJ, Herzog RW. Mapping the T helper cell response to acid α-glucosidase in Pompe mice. Molecular Genetics and Metabolism. 106: 189-95. PMID 22494547 DOI: 10.1016/j.ymgme.2012.03.009  1
2012 Liao G, Detre C, Berger SB, Engel P, de Waal Malefyt R, Herzog RW, Bhan AK, Terhorst C. Glucocorticoid-induced tumor necrosis factor receptor family-related protein regulates CD4(+)T cell-mediated colitis in mice. Gastroenterology. 142: 582-591.e8. PMID 22155173 DOI: 10.1053/j.gastro.2011.11.031  1
2012 Sabatino DE, Nichols TC, Merricks E, Bellinger DA, Herzog RW, Monahan PE. Animal models of hemophilia. Progress in Molecular Biology and Translational Science. 105: 151-209. PMID 22137432 DOI: 10.1016/B978-0-12-394596-9.00006-8  1
2011 Moghimi B, Zolotukhin I, Sack BK, Herzog RW, Cao O. High Efficiency Ex Vivo Gene Transfer to Primary Murine B Cells Using Plasmid or Viral Vectors. Journal of Genetic Syndromes & Gene Therapy. 2. PMID 23565344 DOI: 10.4172/2157-7412.1000103  1
2011 Nayak S, Sarkar D, Perrin GQ, Moghimi B, Hoffman BE, Zhou S, Byrne BJ, Herzog RW. Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B. Frontiers in Microbiology. 2: 244. PMID 22279442 DOI: 10.3389/fmicb.2011.00244  1
2011 Herzog RW, Davidoff AM, Markusic DM, Nathwani AC. AAV vector biology in primates: finding the missing link? Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1923-4. PMID 22051598 DOI: 10.1038/mt.2011.218  1
2011 Martino AT, Herzog RW, Anegon I, Adjali O. Measuring immune responses to recombinant AAV gene transfer. Methods in Molecular Biology (Clifton, N.J.). 807: 259-72. PMID 22034034 DOI: 10.1007/978-1-61779-370-7_11  0.36
2011 Rogers GL, Martino AT, Aslanidi GV, Jayandharan GR, Srivastava A, Herzog RW. Innate Immune Responses to AAV Vectors. Frontiers in Microbiology. 2: 194. PMID 21954398 DOI: 10.3389/fmicb.2011.00194  1
2011 Moghimi B, Sack BK, Nayak S, Markusic DM, Mah CS, Herzog RW. Induction of tolerance to factor VIII by transient co-administration with rapamycin. Journal of Thrombosis and Haemostasis : Jth. 9: 1524-33. PMID 21585650 DOI: 10.1111/j.1538-7836.2011.04351.x  1
2011 Byrne BJ, Falk DJ, Pacak CA, Nayak S, Herzog RW, Elder ME, Collins SW, Conlon TJ, Clement N, Cleaver BD, Cloutier DA, Porvasnik SL, Islam S, Elmallah MK, Martin A, et al. Pompe disease gene therapy. Human Molecular Genetics. 20: R61-8. PMID 21518733 DOI: 10.1093/hmg/ddr174  1
2011 Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, Moghimi B, Ertl HC, Muruve DA, Lee B, Herzog RW. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood. 117: 6459-68. PMID 21474674 DOI: 10.1182/blood-2010-10-314518  1
2011 Hoffman BE, Martino AT, Sack BK, Cao O, Liao G, Terhorst C, Herzog RW. Nonredundant roles of IL-10 and TGF-β in suppression of immune responses to hepatic AAV-factor IX gene transfer. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1263-72. PMID 21386826 DOI: 10.1038/mt.2011.33  1
2011 Jayandharan GR, Aslanidi G, Martino AT, Jahn SC, Perrin GQ, Herzog RW, Srivastava A. Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy. Proceedings of the National Academy of Sciences of the United States of America. 108: 3743-8. PMID 21321191 DOI: 10.1073/pnas.1012753108  1
2010 Markusic DM, Herzog RW, Aslanidi GV, Hoffman BE, Li B, Li M, Jayandharan GR, Ling C, Zolotukhin I, Ma W, Zolotukhin S, Srivastava A, Zhong L. High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 2048-56. PMID 20736929 DOI: 10.1038/mt.2010.172  1
2010 Verma D, Moghimi B, LoDuca PA, Singh HD, Hoffman BE, Herzog RW, Daniell H. Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proceedings of the National Academy of Sciences of the United States of America. 107: 7101-6. PMID 20351275 DOI: 10.1073/pnas.0912181107  1
2010 Herzog RW, Cao O, Srivastava A. Two decades of clinical gene therapy--success is finally mounting. Discovery Medicine. 9: 105-11. PMID 20193635  1
2010 Liao G, Nayak S, Regueiro JR, Berger SB, Detre C, Romero X, de Waal Malefyt R, Chatila TA, Herzog RW, Terhorst C. GITR engagement preferentially enhances proliferation of functionally competent CD4+CD25+FoxP3+ regulatory T cells. International Immunology. 22: 259-70. PMID 20139172 DOI: 10.1093/intimm/dxq001  1
2010 Nayak S, Herzog RW. Progress and prospects: Immune responses to viral vectors Gene Therapy. 17: 295-304. PMID 19907498 DOI: 10.1038/gt.2009.148  1
2010 Jayandharan GR, Zhong L, Sack BK, Rivers AE, Li M, Li B, Herzog RW, Srivastava A. Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses. Human Gene Therapy. 21: 271-83. PMID 19788390 DOI: 10.1089/hum.2009.100  0.72
2009 Sack BK, Herzog RW. Evading the immune response upon in vivo gene therapy with viral vectors. Current Opinion in Molecular Therapeutics. 11: 493-503. PMID 19806497  0.72
2009 Martino AT, Nayak S, Hoffman BE, Cooper M, Liao G, Markusic DM, Byrne BJ, Terhorst C, Herzog RW. Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity. Plos One. 4: e6376. PMID 19652717 DOI: 10.1371/journal.pone.0006376  1
2009 Cao O, Hoffman BE, Moghimi B, Nayak S, Cooper M, Zhou S, Ertl HC, High KA, Herzog RW. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1733-42. PMID 19603001 DOI: 10.1038/mt.2009.159  1
2009 Nayak S, Cao O, Hoffman BE, Cooper M, Zhou S, Atkinson MA, Herzog RW. Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells Journal of Thrombosis and Haemostasis. 7: 1523-1532. PMID 19583824 DOI: 10.1111/j.1538-7836.2009.03548.x  1
2009 LoDuca PA, Hoffman BE, Herzog RW. Hepatic gene transfer as a means of tolerance induction to transgene products. Current Gene Therapy. 9: 104-14. PMID 19355868  1
2009 Cooper M, Nayak S, Hoffman BE, Terhorst C, Cao O, Herzog RW. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Human Gene Therapy. 20: 767-76. PMID 19309290 DOI: 10.1089/hum.2008.161  1
2009 Niemeyer GP, Herzog RW, Mount J, Arruda VR, Tillson DM, Hathcock J, van Ginkel FW, High KA, Lothrop CD. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood. 113: 797-806. PMID 18957684 DOI: 10.1182/blood-2008-10-181479  1
2008 Zhong L, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, Herzog RW, Weigel-Van Aken KA, Hobbs JA, Zolotukhin S, Muzyczka N, Srivastava A. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology. 381: 194-202. PMID 18834608 DOI: 10.1016/j.virol.2008.08.027  0.32
2008 Hoffman BE, Herzog RW. Coaxing the liver into preventing autoimmune disease in the brain. The Journal of Clinical Investigation. 118: 3271-3. PMID 18802483 DOI: 10.1172/JCI37079  1
2008 Cao O, Herzog RW. TLR3 signaling does not affect organ-specific immune responses to factor IX in AAV gene therapy. Blood. 112: 910-1. PMID 18650463 DOI: 10.1182/blood-2008-02-137992  1
2008 Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, Herzog RW, Zolotukhin I, Warrington KH, Weigel-Van Aken KA, Hobbs JA, Zolotukhin S, Muzyczka N, Srivastava A. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proceedings of the National Academy of Sciences of the United States of America. 105: 7827-32. PMID 18511559 DOI: 10.1073/pnas.0802866105  1
2008 Herzog RW, Arruda VR. Substantial immune suppression required in gene therapy for muscular dystrophy? Neuromuscular Disorders : Nmd. 18: 83-4. PMID 18365340  1
2008 Tai SJ, Herzog RW, Margaritis P, Arruda VR, Chu K, Golden JA, Labosky PA, High KA. A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X. Journal of Thrombosis and Haemostasis : Jth. 6: 339-45. PMID 18036190 DOI: 10.1111/j.1538-7836.2007.02849.x  1
2007 Cao O, Furlan-Freguia C, Arruda VR, Herzog RW. Emerging role of regulatory T cells in gene transfer. Current Gene Therapy. 7: 381-90. PMID 17979684  1
2007 Hoffman BE, Dobrzynski E, Wang L, Hirao L, Mingozzi F, Cao O, Herzog RW. Muscle as a target for supplementary factor IX gene transfer. Human Gene Therapy. 18: 603-13. PMID 17594244 DOI: 10.1089/hum.2007.042  1
2007 Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, Terhorst C, Herzog RW. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood. 110: 1132-40. PMID 17438084 DOI: 10.1182/blood-2007-02-073304  1
2006 Herzog RW, Cao O, Hagstrom JN, Wang L. Gene therapy for treatment of inherited haematological disorders. Expert Opinion On Biological Therapy. 6: 509-22. PMID 16610980 DOI: 10.1517/14712598.6.5.509  1
2006 Cao O, Armstrong E, Schlachterman A, Wang L, Okita DK, Conti-Fine B, High KA, Herzog RW. Immune deviation by mucosal antigen administration suppresses gene-transfer-induced inhibitor formation to factor IX. Blood. 108: 480-6. PMID 16543469 DOI: 10.1182/blood-2005-11-4668  1
2006 Dobrzynski E, Fitzgerald JC, Cao O, Mingozzi F, Wang L, Herzog RW. Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America. 103: 4592-7. PMID 16537361 DOI: 10.1073/pnas.0508685103  1
2005 Dobrzynski E, Herzog RW. Tolerance induction by viral in vivo gene transfer. Clinical Medicine & Research. 3: 234-40. PMID 16303889  1
2005 Wang L, Herzog RW. AAV-mediated gene transfer for treatment of hemophilia. Current Gene Therapy. 5: 349-60. PMID 15975012  1
2005 Wang L, Dobrzynski E, Schlachterman A, Cao O, Herzog RW. Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood. 105: 4226-34. PMID 15713796 DOI: 10.1182/blood-2004-03-0848  1
2005 Schuettrumpf J, Herzog RW, Schlachterman A, Kaufhold A, Stafford DW, Arruda VR. Factor IX variants improve gene therapy efficacy for hemophilia B. Blood. 105: 2316-23. PMID 15550487 DOI: 10.1182/blood-2004-08-2990  1
2005 Arruda VR, Stedman HH, Nichols TC, Haskins ME, Nicholson M, Herzog RW, Couto LB, High KA. Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood. 105: 3458-64. PMID 15479726 DOI: 10.1182/blood-2004-07-2908  1
2004 Liu YL, Mingozzi F, Rodriguéz-Colôn SM, Joseph S, Dobrzynski E, Suzuki T, High KA, Herzog RW. Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector. Human Gene Therapy. 15: 783-92. PMID 15319035 DOI: 10.1089/1043034041648453  1
2004 Sabatino DE, Armstrong E, Edmonson S, Liu YL, Pleimes M, Schuettrumpf J, Fitzgerald J, Herzog RW, Arruda VR, High KA. Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene. Blood. 104: 2767-74. PMID 15217833 DOI: 10.1182/blood-2004-03-1028  1
2004 Herzog RW, Dobrzynski E. Immune implications of gene therapy for hemophilia. Seminars in Thrombosis and Hemostasis. 30: 215-26. PMID 15118933 DOI: 10.1055/s-2004-825635  1
2004 Dobrzynski E, Mingozzi F, Liu YL, Bendo E, Cao O, Wang L, Herzog RW. Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. Blood. 104: 969-77. PMID 15105293 DOI: 10.1182/blood-2004-03-0847  1
2004 Arruda VR, Schuettrumpf J, Herzog RW, Nichols TC, Robinson N, Lotfi Y, Mingozzi F, Xiao W, Couto LB, High KA. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood. 103: 85-92. PMID 12969984 DOI: 10.1182/blood-2003-05-1446  1
2003 Herzog RW, Arruda VR. Update on gene therapy for hereditary hematological disorders. Expert Review of Cardiovascular Therapy. 1: 215-32. PMID 15030282 DOI: 10.1586/14779072.1.2.215  1
2003 Mingozzi F, Liu YL, Dobrzynski E, Kaufhold A, Liu JH, Wang Y, Arruda VR, High KA, Herzog RW. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. The Journal of Clinical Investigation. 111: 1347-56. PMID 12727926 DOI: 10.1172/JCI16887  1
2003 Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, Tai SJ, Ragni MV, Thompson A, Ozelo M, Couto LB, Leonard DG, Johnson FA, McClelland A, Scallan C, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 101: 2963-72. PMID 12515715 DOI: 10.1182/blood-2002-10-3296  1
2002 Mingozzi F, Schüttrumpf J, Arruda VR, Liu Y, Liu YL, High KA, Xiao W, Herzog RW. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector. Journal of Virology. 76: 10497-502. PMID 12239326  1
2002 Herzog RW, Fields PA, Arruda VR, Brubaker JO, Armstrong E, McClintock D, Bellinger DA, Couto LB, Nichols TC, High KA. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Human Gene Therapy. 13: 1281-91. PMID 12162811 DOI: 10.1089/104303402760128513  1
2002 Mount JD, Herzog RW, Tillson DM, Goodman SA, Robinson N, McCleland ML, Bellinger D, Nichols TC, Arruda VR, Lothrop CD, High KA. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood. 99: 2670-6. PMID 11929752  1
2001 Arruda VR, Fields PA, Milner R, Wainwright L, De Miguel MP, Donovan PJ, Herzog RW, Nichols TC, Biegel JA, Razavi M, Dake M, Huff D, Flake AW, Couto L, Kay MA, et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Molecular Therapy : the Journal of the American Society of Gene Therapy. 4: 586-92. PMID 11735343 DOI: 10.1006/mthe.2001.0491  1
2001 Fields PA, Arruda VR, Armstrong E, Chu K, Mingozzi F, Hagstrom JN, Herzog RW, High KA. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9 Molecular Therapy. 4: 201-210. PMID 11545610 DOI: 10.1006/mthe.2001.0441  1
2001 Herzog RW, Mount JD, Arruda VR, High KA, Lothrop CD. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation Molecular Therapy. 4: 192-200. PMID 11545609 DOI: 10.1006/mthe.2001.0442  1
2001 Fields PA, Armstrong E, Hagstrom JN, Arruda VR, Murphy ML, Farrell JP, High KA, Herzog RW. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice. Gene Therapy. 8: 354-61. PMID 11313811 DOI: 10.1038/  1
2001 Arruda VR, Hagstrom JN, Deitch J, Heiman-Patterson T, Camire RM, Chu K, Fields PA, Herzog RW, Couto LB, Larson PJ, High KA. Posttranslational modifications of recombinant myotube-synthesized human factor IX Blood. 97: 130-138. PMID 11133752 DOI: 10.1182/blood.V97.1.130  1
2000 Herzog RW, Arruda VR, Fisher TH, Read MS, Nichols TC, High KA. Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony Thrombosis and Haemostasis. 84: 352-354. PMID 10959714  1
2000 Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, McCleland ML, Hagstrom JN, Pasi KJ, Ertl HCJ, Herzog RW, High KA. Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IX Molecular Therapy. 1: 225-235. PMID 10933938 DOI: 10.1006/mthe.2000.0032  1
2000 Hagstrom JN, Couto LB, Scallan C, Burton M, McCleland ML, Fields PA, Arruda VR, Herzog RW, High KA. Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter Blood. 95: 2536-2542. PMID 10753832  1
2000 Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nature Genetics. 24: 257-61. PMID 10700178 DOI: 10.1038/73464  1
1999 Herzog RW, High KA. Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy Thrombosis and Haemostasis. 82: 540-546. PMID 10605748  1
1999 Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, Burton M, Bellinger DA, Read MS, Brinkhous KM, Podsakoff GM, Nichols TC, Kurtzman GJ, High KA. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nature Medicine. 5: 56-63. PMID 9883840 DOI: 10.1038/4743  1
1998 Herzog RW, High KA. Problems and prospects in gene therapy for hemophilia Current Opinion in Hematology. 5: 321-326. PMID 9776210  1
1998 Nakai H, Herzog RW, Hagstrom JN, Walter J, Kung SH, Yang EY, Tai SJ, Iwaki Y, Kurtzman GJ, Fisher KJ, Colosi P, Couto LB, High KA. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood. 91: 4600-7. PMID 9616156  1
1998 Redkar RJ, Herzog RW, Singh NK. Transcriptional activation of the Aspergillus nidulans gpdA promoter by osmotic signals. Applied and Environmental Microbiology. 64: 2229-31. PMID 9603839  1
1997 Herzog RW, Singh NK, Urry DW, Daniell H. Expression of a synthetic protein-based polymer (elastomer) gene in Aspergillus nidulans. Applied Microbiology and Biotechnology. 47: 368-72. PMID 9163950  1
1997 Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher KJ, High KA. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proceedings of the National Academy of Sciences of the United States of America. 94: 5804-9. PMID 9159155 DOI: 10.1073/pnas.94.11.5804  1
1995 Herzog RW, Singh NK, Schmidt C, Lemke PA. Presence of a P1 bacteriophage sequence in transforming plasmids of Pleurotus ostreatus. Current Genetics. 27: 460-5. PMID 7586033  1
Show low-probability matches.